I joined Memorial Sloan Kettering in 1998 as a postdoctoral researcher with a PhD in high-energy physics from Columbia University. My early work here focused on the effects of organ motion in radiation therapy of the prostate and lungs.
I joined the faculty of a regional network site as an assistant chief physicist, where I continued to study the effects of organ motion, particularly in the lungs, and the impact of intensity-modulated radiation therapy on the shielding design for linear accelerators.
Later, I returned to the main campus to join the Department of Medical Physics’ External Beam Treatment Planning section, where I focused on developing new planning techniques for head and neck cancer. I also played a role in developing our image-guided radiation therapy program. In 2009, I was appointed Section Head of External Beam Treatment Planning.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James G. Mechalakos discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures